2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1110 Efficacy and safety of obinutuzumab in the treatment of autoimmune hemolytic anemia

Miao Chen, MD, Yingzhe ju2
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
2 Department of Hematology, Beijing No.6 Hospital, Beijing, China, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China

Objective: To evaluate the efficacy and safety of obinutuzumab in patients with autoimmune hemolytic anemia (AIHA).

Methods: This was a two center, retrospective case series analysis. Clinical data of AIHA patients treated with obinutuzumab between January 2023 and June 2026 were collected, including demographic characteristics, AIHA subtype, prior treatment history, laboratory parameters, and obinutuzumab dosing regimens. Efficacy and safety were assessed. Response criteria: complete response (CR) was defined as hemoglobin ≥120 g/L and transfusion independence; partial response (PR) was defined as hemoglobin increase ≥20 g/L from baseline and transfusion independence without meeting CR criteria; no response (NR) was defined as failure to achieve the above criteria.

Results: A total of 25 patients (10 males, 15 females) were enrolled, with a median age of 60 (range, 18–82) years. The median number of prior treatment lines was 3 (range, 1–7), and 21 patients were relapsed/refractory. Median follow up was 11 (range, 3–22) months. Patients with wAIHA received obinutuzumab 1000 mg on days 1 and 15; patients with mAIHA and cAIHA received 1000 mg weekly for 4 doses. At 1, 3, and 6 months, the overall response rates (ORR, including CR and PR) were 35%, 86.4%, and 88.9%, respectively, and the CR rates were 0%, 31.8%, and 33.3%, respectively. Median time to first PR was 46 (range, 3–306) days, median time to first CR was 73 (range, 32–168) days, and median duration of response was 270 (range, 43–600) days. At last follow up, 22 of 25 patients (95.7%) who achieved response remained in remission. Median hemoglobin levels at 1, 3, and 6 months increased from baseline 79 g/L to 95 g/L, 106 g/L, and 110 g/L, respectively (all P < 0.01). B cell depletion was defined as B cell count <5/μL; evaluable patients at 3 and 6 months numbered 9 and 8, respectively, with depletion rates of 8/9 (88.89%) and 8/8 (100%). Eighteen patients received concomitant corticosteroids; at the end of follow up, 11 (61.1%) discontinued steroids, 3 (16.7%) tapered to prednisone ≤5 mg/d, and 2 (11.1%) had a ≥50% reduction from baseline steroid dose, yielding a steroid reduction/discontinuation rate of 88.9% (16/18). In 18 patients with >6 months of follow up, subgroup analysis showed 6 month ORR of 91.7% for primary vs. 83.3% for secondary AIHA (P = 0.529); 92.3% for wAIHA, 66.7% for cAIHA, and 100% for mAIHA (P = 0.553); and 75% for treatment naïve vs. 92.9% for relapsed/refractory patients (P = 0.732). Three patients previously treated with rituximab (1 rituximab refractory, 2 relapsed) achieved a 6 month ORR of 100%, with 1 CR. Safety: infusion related reactions occurred in 28% of patients, all grade 1–2; infection events occurred in 4% (1 upper respiratory tract infection). No hepatitis B reactivation or treatment related deaths were reported.

Conclusion: Obinutuzumab demonstrates favorable efficacy and a manageable safety profile in patients with AIHA.

Keywords:Autoimmune hemolytic anemia; Obinutuzumab; Efficacy; Safety
Yingzhe ju: No relevant conflicts of interest to declare.